An investigator-initiated section 2 examine (NCT03501979) investigated the mixture of tucatinib (Tukysa), trastuzumab, and capectiabine for treating leptomeningeal metastasis (LM), a variety of most cancers to the membranes surrounding the mind and spinal twine, in sufferers with HER2-positive breast most cancers.
Beforehand, therapy choices for LM have been restricted, and prognosis was poor. This drug mixture is already authorised for the same kind of breast most cancers however with out LM involvement.
The examine enrolled 17 sufferers as a substitute of the deliberate 30. Most sufferers had signs and a few had irregular spinal fluid evaluation.
The therapy confirmed promising outcomes. Over a 3rd of sufferers achieved an goal response. All sufferers skilled some scientific profit, together with steady illness or enchancment. Many sufferers with preliminary neurological issues confirmed enchancment. Additional, high quality of life and symptom burden considerably improved for many sufferers, and sufferers lived longer than anticipated with any such most cancers.
That is the primary examine to indicate clear advantages of a systemic drug therapy for LM in HER2-positive breast most cancers. These findings counsel that treating LM with systemic remedy is perhaps a greater preliminary strategy than beforehand used strategies.
Right here, Barbara O’Brien, MD, affiliate professor of neuro-oncology at MD Anderson Most cancers Middle, who introduced findings from the examine on the 2024 American Society of Medical Oncology Annual Assembly, discusses the targets and outcomes.
Transcription:
0:05 | Our examine evaluated the HER2-directed TKI tucatinib with trastuzumab and capecitabine in sufferers with HER2-positive breast most cancers and leptomeningeal metastasis that was newly recognized, and our main finish level was total survival. And we have been additionally CSF pharmacokinetics, in addition to response evaluation, signs, and high quality of life.
0:34 | The examine initially enrolled robustly, however now not enrolled sufferers to tucatinib when it turned FDA authorised. And so the 17 sufferers that have been concerned, we discovered a median total survival of 10 months, which in contrast favorably to the historic management of 4.4 months. So this was beforehand reported. Now we’re reporting on our response response knowledge. And we discovered that over a 3rd of sufferers achieved a composite leptomeningeal response. And in addition nearly all of sufferers had enchancment of their signs that have been current at baseline.
Transcription created with AI and edited for readability.
